Pre-treatment serum lactate dehydrogenase level is an important prognostic factor in high-grade extremity osteosarcoma

Hitt, Ricardo; Fernández, Jesús M.; Conde, Esther; Martínez‐Tello, Francisco J.; Salamanca, Rafael Enrı́quez de; Cortés, Javier; González-Billalabeitia, Enrique

doi:10.1007/s12094-009-0388-9

Cited by 19 publications

(8 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study by Gonzáles-Billalabeitia et al 19 the authors evaluated 66 patients with osteosarcoma from June 1977 to March 2003. They used LDH serum levels as a prognostic factor for global survival rate of patients with osteosarcoma.…”

Section: Discussionmentioning

confidence: 99%

Serum Values of Alkaline Phosphatase and Lactate Dehydrogenase in Osteosarcoma

et al. 2016

View full text Add to dashboard Cite

Objective: To study the relationship between the pre and post chemotherapy (CT) serum levels of alkaline phosphatase (AP) and lactate dehydrogenase (LDH), and the percentage of tumor necrosis (TN) found in specimens after the pre surgical CT in patients with osteosarcoma.Methods: Series of cases with retrospective evaluation of patients diagnosed with osteosarcoma. Participants were divided into two groups according to serum values of both enzymes. The values of AP and LDH were obtained before and after preoperative CT. The percentage of tumor necrosis (TN) of surgical specimens of each patient was also included.Results: One hundred and thirty seven medical records were included from 1990 to 2013. Both the AP as LDH decreased in the patients studied, being the higher in pre CT than post CT. The average LHD decrease was 795.12U/L and AP decrease was 437.40 U/L. The average TN was 34.10 %. There was no statistically significant correlation between the serums values and the percentage of tumoral necrosis.Conclusion: The serum levels values of AP and LDH are not good predictors for the chemotherapy-induced necrosis in patients with osteosarcoma. Level of Evidence IV, Case Series.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum Values of Alkaline Phosphatase and Lactate Dehydrogenase in Osteosarcoma

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Osteosarcoma is a a very aggressive tumor of bone and its treatment remains a challenge (88). A study has reviewed records from patients diagnosed with conventional high-grade osteosarcoma treated with chemotherapy over a 25-year period and has analysed the prognostic significance of LDH, showing that the pre-treatment serum LDH level had an independent prognostic value for both progression-free survival (PFS) and overall survival (OS) in these patients (89). Another multicenter retrospective study has evaluated the clinicopathological characteristics and prognostic factors in 240 Turkish patients with osteosarcoma from March 1995 to September 2011.…”

Section: Ldh As Diagnostic Marker Prognostic Factor and Predictive Mmentioning

confidence: 99%

Lactic dehydrogenase and cancer an overview

Gallo¹,

Sapio²,

Spina

et al. 2015

Front Biosci

View full text Add to dashboard Cite

Despite the intense scientific efforts made, there are still many tumors that are difficult to treat and the percentage of patient survival in the long-term is still too low. Thus, new approaches to the treatment of cancer are needed. Cancer is a highly heterogeneous and complex disease, whose development requires a reorganization of cell metabolism. Most tumor cells downregulate mitochondrial oxidative phosphorylation and increase the rate of glucose consumption and lactate release, independently of oxygen availability (Warburg effect). This metabolic rewiring is largely believed to favour tumor growth and survival, although the underlying molecular mechanisms are not completely understood. Importantly, the correlation between the aerobic glycolysis and cancer is widely regarded as a useful biochemical basis for the development of novel anticancer strategies. Among the enzymes involved in glycolysis, lactate dehydrogenase (LDH) is emerging as a very attractive target for possible pharmacological approaches in cancer therapy. This review addresses the state of the art and the perspectives concerning LDH both as a useful diagnostic marker and a relevant molecular target in cancer therapy and management.

show abstract

“…In humans, it is a surrogate for tissue breakdown due to various causes, including muscle injury, hemolytic anemia, acute coronary syndrome, diverse infectious or inflammatory conditions and certain malignancies. The elevation of LDH in the blood is a relatively nonspecific phenomenon; however, it has been recognized as a tumor marker, as it reflects tumor burden and cellular turnover in several aggressive malignancies, including germ cell tumors [2] , sarcomas [3][4] and nonHodgkin lymphoma (NHL) [5][6] .…”

Section: Introductionmentioning

confidence: 99%

Prognostic Role of Serum Lactate Dehydrogenase Beyond Initial Diagnosis: A Retrospective Analysis of Patients with Diffuse Large B Cell Lymphoma

Hong¹,

Yoon²,

Ahn³

et al. 2013

Acta Haematol

View full text Add to dashboard Cite

Background/Aims: Baseline serum lactate dehydrogenase (LDH) level is a well-known prognostic factor in patients with non-Hodgkin's lymphoma; however, its role beyond initial diagnosis has not yet been defined. Methods: This study was conducted as a retrospective analysis of patients with diffuse large B cell lymphoma (DLBCL) treated with R-CHOP21, who had undergone regular checks for LDH during immunochemotherapy (n = 119) and during the posttreatment follow-up period after complete remission (CR; n = 100). The 119 patients were classified into 4 groups according to their baseline and change in LDH level during treatment, and an analysis of tumor response and survival was performed. The value of LDH as a predictor for relapse was evaluated among the patients with regular follow-up visits after achieving CR. Results: An increased LDH level during immunochemotherapy had no impact on tumor response or survival, and only the LDH status ‘before' treatment was a prognostic marker. The sensitivity, specificity, positive predictive value and negative predictive value of serum LDH for detecting relapse after CR were 47.4, 86.5, 9.3 and 98.3%, respectively. Conclusion: The measurement of LDH level beyond initial diagnosis has no clear benefit in predicting disease progression or relapse in patients with DLBCL treated with R-CHOP21.

show abstract

Pre-treatment serum lactate dehydrogenase level is an important prognostic factor in high-grade extremity osteosarcoma

Abstract: In this series, the pre-treatment serum LDH level had an independent prognostic value for both PFS and OS in patients with high-grade localised extremity osteosarcoma. This measurement should be included in a large prospective prognostic series.

Cited by 19 publications

References 27 publications

Serum Values of Alkaline Phosphatase and Lactate Dehydrogenase in Osteosarcoma

Serum Values of Alkaline Phosphatase and Lactate Dehydrogenase in Osteosarcoma

Lactic dehydrogenase and cancer an overview

Prognostic Role of Serum Lactate Dehydrogenase Beyond Initial Diagnosis: A Retrospective Analysis of Patients with Diffuse Large B Cell Lymphoma

Contact Info

Product

Resources

About